Biodesix® Named Innovative Company of the Year at 2016 IQ Awards
Biodesix won the BizIQ award, 2016 Innovative Company of the Year.
×
254 Results
Biodesix won the BizIQ award, 2016 Innovative Company of the Year.
Humana, Medical Mutual of Ohio and Preferred One independently determined and published a policy stating that VeriStrat can be considered medically necessary for patients with (NSCLC)
Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.
VeriStrat® Test identifies patients with squamous cell carcinoma of the lung who are more likely to have improved survival on Afatinib therapy.
Independent Study Data supports clinical use of Biodesix’s blood-based tests at CHEST conference.
Biodesix's VeriStrat test identifies T790M-mutated advanced non-small cell lung cancer patients who are more likely to have improved progression-free survival on third generation EGFR-TKI therapy
Biodesix will present data from three studies at SITC's annual meeting.
Multi-institutional data supporting clinical use of Biodesix blood tests was presented at the IASCL Chicago thoracic conference
The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision
Data from an independent study demonstrated the clinical utiity of Biodesix' VeriStrat and GeneStrat tests.